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INTRODUCTION 
Head and neck cancer 
Head and neck squamous cell carcinoma (HNSCC) is the sixth 
most common cancer worldwide, with an annual incidence of 
approximately 560,000 cases [1]. In Denmark the 2013 incidence 
of head and neck cancer (i.e. laryngeal, pharyngeal, oral cavity, 
sino-nasal and salivary gland cancer and unknown primary) was 
1,287 [2]. This incidence has been increasing over the past 25 
years, also when adjusted for age [3]. The 5-year age-adjusted 
relative survival is 64% for men and 68% for women [4]. This rate 
has been relatively constant for men between 1998 and 2012, but 
has been improving for women.  
The term head and neck cancer covers a heterogeneous group of 
cancer diagnoses and locations, where squamous cell carcinoma 
of the oral cavity, pharynx and larynx is the most common histol-
ogy. The environmental etiology of HNSCC is mainly related to 
tobacco and alcohol intake. However, the incidence of HNSCC 
caused by Human Papillomavirus (HPV) has increased over the 
last 30 years, especially for oropharyngeal cancer [5,6]. This has 
led to a new subgroup of patients with HNSCC, who have differ-
ent clinical characteristics and molecular biology and increased 
radiosensitivity [7,8]. 
 
Treatment of HNSCC 
HNSCC is predominantly a loco-regional disease with less than 5% 
of patients having distant metastases at diagnosis [2]. Around 
60% of patients have locally advanced disease (i.e. stage III and 
VI) at diagnosis. The main treatment options are surgery and 
radiotherapy (RT), either alone or in combination, and in recent 
years with addition of chemotherapy. RT is the primary treatment 
for HNSCC in Denmark [9], thus 70% of patients receive primary 
RT and 30% receive surgery with or without post-operative RT [2]. 
For the majority of patients with early stage HNSCC, single modal-
ity treatment may be sufficient for cure. For patients with ad-
vanced disease, combined modality treatment including chemo-
radiation [10], modification of tumor hypoxia [11] and altered 
fractionation [12,13] has improved outcome. Treatment with 
newer biological targeted agents, like epidermal growth factor 
receptor (EGFR) inhibitor, in combination with definitive RT is 
controversial [14-17].  
Over the past three decades there has been a significant techno-
logical development in the delivery of RT, from two-dimensional 
(2D)-RT based on X-ray images to CT-based three-dimensional 
conformal treatment (3D-CRT). 3D-CRT uses three or more treat-
ment fields to deliver a homogeneous dose to the target area, 
and subsequent implementation of multi-leaf collimators and 
more advanced computer algorithms, has enabled intensity mod-
ulated RT (IMRT) and later volumetric modulated arc therapy 
(VMAT). With these novel treatment techniques there is potential 
for sparing the normal tissues while increasing radiation dose to 
the tumor and other target areas [18-20].   
The Danish Head and Neck Cancer Group (DAHANCA) has used 
standardized guidelines for treatment of head and neck cancer in 
all centers [21] since 2002, and DAHANCA trials have made a 
significant contribution to optimizing RT in patients with head and 
neck cancer, both nationally and internationally [11,12,22]. The 
DAHANCA database contains a variety of clinical, demographic, 
and treatment-related data including symptoms, etiological fac-
tors, diagnostic methods, TNM stage, primary treatment, follow-
up status, disease failure, death and cause of death of patients 
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diagnosed with HNSCC in Denmark since 1991 (and larynx carci-
noma since 1971) [2,23]. The database provides a valuable tool 
for quality assurance of treatment [24] and for research, including 
the present PhD-project [25-29].  
 
Radiation treatment planning  
Treatment is delivered as external beam radiation using linear 
accelerators. In definitive RT for HNSCC in this project, standard 
target dose is 66-68 Gy in 33-34 fractions, 5-6 fractions/week 
[21].Treatment planning for head and neck cancer patients in 
daily practice is initiated with a therapeutic CT-scan of the patient 
fixated in the treatment position. The tumor volume and clinically 
relevant target areas are defined and delineated in the treatment 
planning system by the oncologist and the radiologist in collabo-
ration. The critical normal tissues, organs at risk (OARs), are de-
fined and delineated by the oncologist. Planning target volumes 
are then generated and a dose calculation is performed to ensure 
appropriate dose distributions to cover tumor areas during radio-
therapy and to keep treatment doses below tolerance levels of 
the normal tissues as defined by clinical guidelines. Modern 
treatment planning systems allow a rather precise calculation of 
treatment dose to small areas (submillimeter). Knowledge of 
tolerance levels to ionizing radiation of different organs can be 
used in RT dose-planning to restrict a specific dose (dose-
constraint) or treated volume to an organ using either a single 
value, such as the mean dose to the organ, or by multiple dose-
volume constraints [30]. 
 
Toxicity 
The limiting factor in RT is toxicity of the normal tissues. The 
greatest challenge in radiotherapy is thus to optimize disease 
control while minimizing toxicity to the surrounding normal tis-
sue.  
Toxicity has traditionally been divided into two categories: acute 
reactions, defined as effects that occur within 90 days after start 
of RT, and late reactions which develop ≥90 days after treatment 
(and up to years after RT). The relevance of this separation in 
grading and reporting adverse effects has been challenged inter-
nationally, however, and identification of potential new temporal 
patterns of injury are encouraged [31]. 
Common acute reactions during treatment of HNSCC are pain, 
mucositis, dysphagia, xerostomia, loss of taste, mucosal edema 
and erythema, skin erythema and moist desquamation. Common 
late reactions include xerostomia, dysphagia, mucosal edema and 
skin fibrosis [32].  
Such endpoints generally have been graded on four- or five-point 
scales [33]. Adverse event reporting in cancer treatment, and 
specifically radiation oncology have been the Common Terminol-
ogy Criteria for Adverse Events (CTCAE) [31] and the LENT/SOMA 
scale [34-36]. LENT is an acronym for Late Effects Normal Tissues, 
while SOMA defines toxicity from Subjective, Objective, Man-
agement-related and Analytic measures (i.e. blood test, CT or the 
like). Graded toxicity scorings can be converted into binary data 
to form the basis for analyzing radiation dose-response relation-
ships that can be used to predict toxicity in patients undergoing 
radiation treatment. 
 
Normal tissue complication probability (NTCP) mod-
eling 
Since radiation of normal tissues is inevitable during external 
beam RT, knowledge about tolerance levels of OARs to ionizing 
radiation is necessary to distribute the radiation dose appropri-
ately to avoid unacceptable toxicity. With increasing radiation 
dose, the frequency (i.e. incidence) and the severity (i.e. grade) of 
radiation effects may increase.  
In radiobiological studies, the impact of radiation dose on normal 
tissues (and tumor tissue) is often demonstrated by dose-
response (dose-incidence) curves. Dose-response curves describe 
the probability of a specific response (i.e. radiation effect) as a 
function of dose. They generally have a sigmoid (S-) shape where 
the risk of a given effect goes from 0% or close to at no radiation 
and close to 100% at high doses. Several mathematical functions 
have been used to model the relationship between radiation dose 
and normal tissue complication probability (NTCP); most fre-
quently the Poisson, the logistic, or the probit models [37,38]. For 
endpoints requiring prolonged follow-up, such as late normal 
tissue reactions, these models may be embedded in a so-called 
mixture model, where the time to occurrence of the endpoint is 
also taken into account [39]. Dose-constraints as described above 
are derived from NTCP models and can be defined as dose-
volume restrictions for a clinically acceptable risk of a given radia-
tion effect [21].  
In 1991, Emami et al. [40] pooled information regarding partial or 
total organ tolerance doses with the clinical experience and 
judgments of clinicians and researchers, and published tolerance 
doses for various organs, including the thyroid gland. The subse-
quent development of 3D-CT based treatment planning and the 
possibility of calculating precise doses to normal tissues have 
enabled studies of normal tissue response in relation to different 
dosimetric parameters. In 2010, extended analyses applying 
volume modeling of normal tissue reactions in clinical radiothera-
py were published in the Qualitative Analysis of Normal Tissue 
Effects in the Clinic (QUANTEC) papers [41]. However, data re-
garding normal tissue reactions of the thyroid gland was omitted 
by the QUANTEC group. 
 
The thyroid gland 
The thyroid gland is located in the lower region of the neck, in 
relation to the lower part of the larynx and upper part of the 
trachea. The gland consists of two lobes, right and left, which are 
connected through the isthmus. The size of the thyroid gland in 
the Danish population was 15-28 ml [42], but after the introduc-
tion of salt iodization around 2000, this size seems to have de-
creased [43]. 
The follicle cells of the thyroid gland synthesize and secrete the 
hormones thyroxine (T4) and triiodothyronine (T3). These thyroid 
hormones regulate the metabolism of tissues and organs in man, 
and are tightly genetically regulated in healthy individuals, as 
shown e.g. in twin studies [44]. Thyroid hormones also influence 
most of the pathways of intermediary metabolism. If thyroid 
hormones are deficient, pathways of carbohydrate, lipid and 
protein metabolism are slowed, as is pathways’ responsiveness to 
other regulatory factors. Thyroid hormones are also essential for 
normal body growth and the development of the central nervous 
system, especially in the pre- and postnatal period. 
Thyroid function is regulated by a delicate negative feedback loop 
between mainly the pituitary and the thyroid through secretion of 
thyrotropin (TSH) from the anterior pituitary, and T4 and T3 from 
the thyroid. TSH secretion is stimulated by thyrotropin-releasing 
hormone (TRH) from the hypothalamus but a complicated net-
work of hormonal and non-hormonal factors, which will not be 
dealt with here, influences the serum TSH level. The hypothalam-
ic-pituitary-thyroid axis follows a diurnal circadian rhythm, with 
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low TSH levels in the daytime and higher levels at night [45,46] in 
individuals following a normal day-night sleep-awake rhythm. 
 
Pathophysiology and mechanism of radiation-
induced injury 
Damage to the thyroid gland by ionizing RT is due to a variety of 
pathological mechanisms. These include vascular effects in the 
epithelium of small vessels and the development of fibrosis of 
capsular structures, while the damage to the follicular epithelial 
cells is considered less important [47,48]. Ultrasonography has 
shown that changes in both the blood vessels and the gland 
echogenicity occur during RT, and subsequent development of 
acute thyroiditis was correlated to vessel changes [49]. The pre-
dominant late morphological changes consist of atrophy, chronic 
inflammation (thyroiditis) with lymphocytic infiltration, vascular 
fibrosis, and focal and irregular follicular hyperplasia [47,50,51]. 
The mechanisms for radiation-induced hypothyroidism are largely 
unknown but are assumed to be related to vascular damage [48]. 
 
Hypothyroidism 
Hypothyroidism (HT) is defined as decreased function of the 
thyroid gland and is characterized by TSH above the normal range 
(at Odense University Hospital the normal range is 0.3-4.0 mIU/l 
[52]). HT can be subclinical HT (SHT) with elevated TSH and nor-
mal T4 and T3, or overt HT with elevated TSH and T4 and/or T3 
below the normal range. 
 Hypothyroidism, including SHT, has been linked to a number of 
metabolic changes such as hyperlipidemia [53], coagulopathy 
[54], endothelial dysfunction [55] and other cardiovascular disor-
ders [56,57]. These changes are associated with increased mor-
bidity such as cardiovascular diseases, lung diseases and diabetes 
mellitus [58]. HT has also been associated with psychiatric mor-
bidity [59] and impaired quality of life [60,61]. Although effects on 
mortality have been uncertain [62], two recent Danish studies 
have found increased mortality in patients with overt HT com-
pared to euthyroid controls [63,64]. While SHT has been linked to 
an increased risk of coronary heart disease [65,66] and mortality 
[67-70], the effect on overall mortality is still a matter of debate 
[64,66,67,69,71] and duration of thyroid dysfunction may matter 
[64]. For these reasons, radiation to the thyroid gland must be 
considered in RT of head and neck cancer. 
The prevalence of HT is 1-2% [72]. In Denmark, the lifetime risk of 
overt HT has been reported to be 2.7% (with a 3:1 female pre-
dominance) [73]. The prevalence of SHT increases with age and in 
the age group 60-65 years the prevalence is 7.1% for women and 
1.6% for men [74]. Substitution treatment with Levothyroxine is 
indicated in overt HT and some cases of SHT [75]. 
Development of HT is influenced by a number of factors such as 
gender [73], genetic predispositions [76] and environmental 
factors of which iodine intake and cigarette smoking are best 
characterized [77-79]. In a Danish study of overt HT, Carlé et al. 
[73] found that the dominant cause of HT was spontaneous HT 
(85%), mostly of autoimmune origin, while non-spontaneous HT 
was caused by post-partum thyroiditis (4.7%), medications such 
as Amiodarone (4.0%) or Lithium (1.6%), subacute thyroiditis 
(1.9%), congenital (1.6%), and previous treatment with radioio-
dine, external beam radiation and surgery (1.8%). Importantly, 
the prevalence of HT after external beam radiation may well be 
underestimated, since measurements of TSH after RT have until 
now not been performed routinely in Danish oncology centers. 
 
Background for the PhD project 
Radiation- induced HT (RIHT) was a recognized late effect of RT to 
the neck when this PhD project was initiated [47,80-95]. Howev-
er, the reported incidences varied significantly as the design, 
endpoint, and treatment regimes in previous studies were differ-
ent. Overt HT was reported in 6-20% of head and neck cancer 
patients [80,81,83,85,90,95] and SHT in 24-50% [82,87,88,91-
93,95]. The role of chemotherapy as a risk factor of RIHT was 
unclear [84-86], but surgery seemed to be critical [81-
83,87,89,94,95]. Table 1 shows an overview of studies. 
No relevant Danish data was available on the incidence of RIHT, 
and TSH assessment after RT had not been part of the national 
routine follow-up of head and neck cancer patients. Furthermore, 
the tolerance dose of the thyroid gland to ionizing radiation was 
poorly defined. Data had been derived from only a few studies 
that were able to report calculated absorbed doses to the thyroid 
gland (see Table 1). Consequently, the radiotherapy units of Dan-
ish oncology centers did not routinely consider calculated radia-
tion doses to the thyroid gland when optimizing radiation treat-
ment plans. 
 
Aims 
Overall aims of the PhD project 
1. To estimate the incidence of biochemical hypothyroid-
ism in a large cohort of patients with head and neck 
squamous cell carcinoma (HNSCC) of the oral cavity, 
oropharynx, hypopharynx, and larynx treated with de-
finitive radiotherapy and no surgery, and to assess the 
time-course of the development of hypothyroidism. 
2. To establish a dose-response relationship for biochemi-
cal hypothyroidism by assessing the absorbed radiation 
doses in the thyroid gland in individual patients and 
thus to estimate the tolerance level of the thyroid gland 
to ionizing radiation.  
 
Aims of the studies 
Study I: 
1. To identify risk factors for hypothyroidism after defini-
tive radiotherapy for HNSCC. 
2. To establish an NTCP dose-response relationship for bi-
ochemical hypothyroidism. 
3. To provide clinical recommendations for thyroid con-
straints in dose planning for radiotherapy.  
 
Study II: Validation of input data 
1. To evaluate the variability of estimated NTCP values 
from the mixture NTCP model derived in study I and to 
assess the intra- and inter-observer variability in deline-
ation of the thyroid gland. 
 
Study III: Validation of the NTCP model 
1. To investigate risk factors for hypothyroidism in a new, 
independent population of HNSCC patients. 
2. To generate an (equivalent) NTCP model for comparison 
with the original data set to test the robustness of the 
previous NTCP model. 
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Table 1. Overview over studies on radiation-induced hypothyroidism (RIHT). (Studies published after the start of this PhD project have a 
grey background).  
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MATERIAL AND METHODS 
This thesis is based on three studies. The first study was a retro-
spective cohort study from the Department of Oncology, Odense 
University Hospital (OUH), studying the incidence and risk factors 
for RIHT and development of an NTCP model for RIHT after defini-
tive radiotherapy for HNSCC. The second study was a validation of 
the input data in Study I, assessing the impact of observer varia-
bility in delineation of the thyroid gland on the estimates from 
the NTCP model. The third study was a validation of the NTCP 
model from Study I on a similar cohort of HNSCC patients treated  
at another center, the Department of Oncology at Aarhus Univer-
sity Hospital (AUH). 
An overview of the designs, methods, data and analyses are pre-
sented in Table 2. Further details are provided in the following 
sections. 
 
Table 2. Overview of the methods used in the three studies of this 
thesis. 
 
 
Study I 
Study population 
Participants were patients with HNSCC in the oral cavity, orophar-
ynx, hypopharynx or larynx treated with definitive RT (66-68 Gy in 
33-34 fractions) with or without concomitant chemotherapy at 
the Department of Oncology, OUH, in the period 2002-2010 
(cohort1).  Inclusion- and exclusion criteria and patient character-
istics are described in Paper I. 
2002 was chosen as the start of the study period, as all head and 
neck cancer patients treated at OUH from 2002 received treat-
ment according to a CT-based 3D treatment plan that had been 
stored after treatment. 
 
Material 
The study was designed as a retrospective cohort study with both 
prospective and retrospective collection of TSH assessments. 
HNSCC patients treated in the period 2002-2010 were identified 
from the DAHANCA database, see Figure 1. The clinical data from 
this database were crosschecked with patient charts. Missing data 
values were corrected, and information about thyroid disease and 
medication were collected. 
 
 
 
TSH assessment 
Patients were considered euthyroid if they had a normal TSH 
measurement within the last year before RT or in the first two 
weeks of RT (baseline TSH). Follow-up TSH assessments were 
obtained after the end of RT.   
All TSH analyses were done at the Department of Biochemistry 
and Pharmacology (KBF) at OUH and the data were extracted 
from the OUH laboratory database (Netlab). All TSH assessments 
in the database were taken into account (i.e. from all OUH de-
partments and from general practitioners in the county of Funen). 
The time period for data extraction was January 2001- March 
2012. 
Until 2006, serum TSH was measured using a time-resolving 
fluoroimmunometric assay (AutoDELFIA, Perkin Elmer, Turku, 
Finland), reference interval 0.30-4.0 mIU/l [52]. The intra- and 
inter-assay coefficients of variation (CVs) at serum TSH concentra-
tions 0.046-17.6 mIU/l were 1.3-4.7% and 1.7-3.7%, respectively. 
From 2006 to September 2010, serum TSH was analyzed using a 
solid-phase, two-site chemiluminescent immunometric assay 
(third generation assay) on Immunolite 2000 equipment (Sie-
mens, Erlangen, Germany). The intra- and inter-assay CVs at 
serum TSH concentrations 0.32-39 mIU/l were 3.8-5.3% and 4.5-
6.4%, respectively. After September 2010, plasma TSH has been 
analyzed using a different third generation assay (Architect i 
system, Abbot, Wiesbaden, Germany). The intra- and inter-assay 
CVs at plasma TSH concentrations 0.088-28.4 mIU/l were 1.4-
5.0% and 1.7-5.3%, respectively. To ensure compatibility between 
the different equipment, comparisons were done at KBF when 
equipment was replaced, and the same reference interval for TSH 
has been applied for all three methods.  
Before 2008, TSH assessments of HNSCC patients were obtained 
at the Department of Oncology, OUH, when indicated. In 2008, a 
guideline for routine assessment of thyroid function in HNSCC 
patients was implemented, i.e. TSH and T3/T4 when indicated, 
before RT and once a year after RT. To include more patients from 
the first half of the study period, additional baseline TSH assess-
ments were obtained from blood bank samples collected from 
participants in the DAHANCA 10 trial [111] (EDTA-plasma stored 
at – 80°C, analyzed in June 2011). Blood samples from 45 patients 
were analyzed, and 27 of these were included in the study. Anal-
yses of TSH on EDTA-plasma compared to Li-heparin plasma were 
validated at KBF, OUH, by collecting blood samples from 20 
healthy individuals (10 men and 10 women) aged 20-70 years. 
Analyses were done using the standard assay on Architect and 
showed no significant differences between the two types of 
plasma (p=0.423).  
Patients eligible for this study who had finished scheduled follow-
ups were invited for additional TSH assessment. Of the 38 pa-
tients invited, 23 (61%) accepted and gave a blood sample after 
informed consent.  
 
Delineation of the thyroid gland 
Treatment dose-planning was done in Pinnacle3 (Philips 
Healthcare, The Netherlands). The thyroid gland was not previ-
ously delineated, so the author (MFR) delineated the gland in all 
treatment plans. After delineation, the precise treatment dose to 
the gland was calculated and the corresponding dose-volume 
histograms (DVH) were exported for analysis. Thyroid gland vol-
ume (Vthyroid) and mean (Dmean), maximal (Dmax) and minimal dose 
(Dmin) as well as V10 (defined as the percentage volume receiving 
10 Gy or more), V20, etc. up to V70 were extracted from the DVHs.  
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Five of the included patients received treatment from two treat-
ment plans. Here, the dose to the thyroid gland was evaluated in 
each case and if the dose per fraction was not significantly differ-
ent in the two plans, the treatment plan used for the majority of 
fractions was chosen (n=4). Otherwise, the doses were corrected 
for the number of fractions given and summarized (n=1). 
 
 
Figure 1. Inclusion of patients in Study I 
 
Endpoint 
The endpoint of the study was biochemical hypothyroidism, 
defined as plasma-TSH above the normal range. The normal range 
in the OUH laboratory is 0.30-4.0 mIU/l [52]. The first TSH as-
sessment above the normal range was defined as an event. 
Follow-up was defined as time from the last day of RT to the last 
TSH assessment or censoring.  
 
Statistical methods 
Data were initially analyzed using standard logistic regression. 
Univariable analyses were performed first. Subsequently, the two 
most significant factors were entered into a multivariable model 
and the significance of the other covariates was tested by enter-
ing them into the model one by one. 95% confidence intervals (CI) 
were calculated using the profile likelihood method, and p-values 
were derived from the likelihood ratio (LR) test. The variables 
considered in the analyses were tested for possible interactions.   
Thereafter, data were analyzed using a mixture model. This was 
done using the logistic model and incorporating a latent time 
distribution. First, data were analyzed using two different time 
distributions, a Weibull distribution and a log-logistic distribution, 
representing two different classes of mathematical functions. 
Performance of the two models were evaluated by the models -2 
log likelihood (-2LL) and residuals. There were no statistical dif-
ferences between the two models, but the Weibull distribution 
showed slightly better -2LL and was therefore chosen for further 
analyses. 
All parameters were optimized by maximum likelihood from the 
entire data set [39,112]. The mixture model was analyzed with 
univariable and multivariable analyses equivalently to the logistic 
model described above. 
The significant variables from the multivariable analysis were 
applied to the NTCP models. The 95% CI for the NTCP models 
were derived by bootstrapping (10,000 samples).  
The cumulative incidence of HT was calculated using the mixture 
model. 
Study II 
Study population 
The thyroid gland was delineated in 246 clinically administered 
treatment plans in Study I by MFR, and 50 of these plans were 
randomly selected for this study. 
Patient characteristics and treatment plans are described in Paper 
II.  
 
Material 
The study was designed to assess intra- and inter-observer varia-
bility. The first 50 treatment plans in which the thyroid gland was 
delineated, were excluded from the study to avoid a potential 
bias of a ‘learning curve’ in delineation. Fifty other treatment 
plans were selected from a randomly ordered list for i) blinded re-
delineation of the thyroid gland by MFR (intra-observer) and ii) a 
corresponding delineation of the thyroid by a radiation oncolo-
gist, Jørgen Johansen (JJ) (inter-observer). Re-delineation was 
done at least three months after the first delineation. Guidelines 
were made for blinding the delineated structures in the dose 
plans and naming the structures, but no guideline for the delinea-
tion of the thyroid was given. 
Thyroid Dmean (Gy) and Vthyroid (cm3) from the new delineations 
were obtained from the DVHs in the dose-planning system equiv-
alent to Study I. 
 
Statistical methods 
Differences in intra- and inter-observer delineated Vthyroid, Dmean 
and estimated NTCP of HT were assessed by Bland-Altman plots 
[113]. Wilcoxon signed-rank test was used to check for systematic 
differences and Spearman’s rank correlation was used to test for 
correlation between the paired differences and mean Vthyroid, 
Dmean and NTCP, respectively.  
The correlation between the (random) variation and mean thy-
roid volume was tested by dividing the paired differences into five 
equally-sized groups, depending on mean thyroid size, and testing 
the SDs of these groups with Spearman’s rank correlation. 
The Sørensen-Dice similarity index (DSI) was calculated for over-
lap measure of delineated Vthyroid: 
   
For assessment of spatial variations in delineated volume, the 
thyroid glands were manually divided into two lobes, and map-
ping of each lobe was done using the center of mass as origin and 
100 measurement points in both latitudinal and longitudinal 
direction (10,000 surface points in total). The distance from the 
center to the contours was measured, including the sign 
(plus/minus) indicating whether the first contour was inside or 
outside the second contour. Based on these spatially resolved 
values, population averaged values (systematic deviations) as well 
as SD (random deviations) could be calculated and visualized as a 
color surface plot of the “mean thyroid gland” using the color to 
illustrate the local deviation.  
 
Study III 
Study population 
Participants were patients treated with definitive RT at the De-
partment of Oncology, Aarhus University Hospital (AUH). Patients 
were included after a follow-up TSH measurement that was taken 
when they attended the outpatient clinic for routine follow-up 
(cohort2). Inclusion and exclusion criteria are described in Papers 
I and III, and patient characteristics are presented in Paper III. 
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Material 
The study was a retrospective cohort study to validate the NTCP 
model from Study I. The study was conducted at the Department 
of Oncology, AUH, in collaboration with Odense University Hospi-
tal (OUH).  
 
TSH assessment 
TSH had not previously been assessed routinely after RT at AUH, 
but was implemented as a routine assessment for patients in the 
outpatient clinic at the time of this study (partly on the basis of 
the findings from Study I). A baseline TSH was obtained. Due to 
the study design and lack of routine blood sampling, only one 
follow-up blood test was obtained from the AUH study group. 
To reduce bias due to analysis at different laboratories, all blood 
samples collected during the study time period were analyzed at 
the KBF at OUH. Blood samples were centrifuged, pipetted and 
frozen and sent to Odense for routine analysis. Blood samples 
were analyzed for TSH, TPO-antibodies and, if TSH was outside 
the normal range, total T3 and T4 and free T3 and T4. Baseline 
TSH and TPO-antibodies were analyzed on blood samples (lithi-
um-heparin plasma stored at -80o C) from the blood bank at the 
Department of Experimental Clinical Oncology, AUH. Analyses 
were done in March 2013. 
After collection of a blood sample, the patient’s chart was re-
viewed to assess if the inclusion criteria were met, and the data-
base from the blood bank was searched for a baseline blood 
sample. For the patients included in the study, all data were 
crosschecked with the DAHANCA database, and missing data 
values were corrected. The inclusion process is shown in Figure 2. 
 
 
 Figure 2. Inclusion of patients in Study III 
 
Delineation of the thyroid gland and extraction of dose 
The thyroid gland was delineated by the author (MFR) in all 
treatment plans using Eclipse (Varian, Palo Alto, USA). Thyroid 
volume and radiation doses were calculated. Afterward, the 
treatment plans were exported as DICOM RT data to the DICOM 
Collaboration system (“the CIRRO-server”) at Odense University 
Hospital [114]. Thyroid Dmean and Vthyroid were extracted from the 
recalculated DVHs in the database. The database has a built-in 
data validation and verification function, and the dose and vol-
ume were also double-checked with the values extracted from 
Eclipse after delineation.   
In cohort2, 32 patients received treatment from two treatment 
plans or more. It was therefore necessary to consider a uniform 
method to calculate Dmean to the thyroid gland in these treatment 
plans. Eleven patients were treated using two or more treatment 
plans from one CT scan, while 21 patients were treated using two 
or more treatment plans from two or more CT scans. The Vthyroid 
of the first clinically applied treatment plan was chosen for fur-
ther analysis of volume. The different treatment plans were ex-
ported to the CIRRO server with the total dose corrected for the 
number of fractions given from the corresponding dose plan. 
Dmean values from multiple dose plans in an individual patient 
were extracted from the CIRRO server and the doses were then 
summarized. 
 
Endpoint 
The endpoint was biochemical hypothyroidism and follow-up was 
defined as the time from the last day of RT to the TSH assessment 
(as in Study I). 
 
Statistical methods 
The study was a validation study of the mixture NTCP model 
developed in Study I. Data from cohort2 were thus analyzed in 
the same way as in Study I, and the results were compared with 
cohort1. 
 Due to only one TSH assessment in cohort2 compared to multiple 
blood samples in cohort1, sampling bias was considered. 
 To reduce this potential bias in the comparison of the two co-
horts, a new cohort (cohort1S) was generated from cohort1 by 
taking only one follow-up TSH-assessment into account. This was 
done by 10,000 Monte Carlo samplings. Analyses on cohort1S 
were done on each individual sample and the reported values and 
confidence intervals were obtained from the distribution of val-
ues from all samples (median and standard deviation).  
Latency could not be estimated from cohort2, therefore, the time 
factor (Weibull distribution) from cohort1 was fixed and applied 
to both cohort1S and cohort2.  
More detailed descriptions of the statistical methods are given in 
Papers I and III. Analyses were done using STATA 11 and 13 and 
MATLAB version 2012b. All statistical tests were two-sided and a 
p-value <0.05 was considered statistically significant. 
 
Ethics 
The studies were approved by the Regional Ethics Commit-
tees for Southern Denmark (S-20110027) and the Danish Data 
Protection Agency (J.nr. 2011-41-575 (Study I) and J.nr. 2012-41-
0899 (Study III)). All patients invited for additional TSH measure-
ment signed an informed consent form before the blood sample 
was collected. 
 
RESULTS 
The results of the three studies are summarized here. More de-
tailed results, tables and figures are provided in the three papers 
(see appendix). 
 
 Hypothyroidism after primary radiotherapy for head and neck 
squamous cell carcinoma: normal tissue probability modeling 
with latent time correction (Paper I) 
Two hundred and three patients were included in cohort1. The 
cohort was representative for all HNSCC patients treated with 
definitive RT at our institution in that time period (data not 
shown). A single follow-up TSH measurement was obtained in 96 
patients and two or more (range 2-11) measurements were ob-
tained in 112 patients. HT occurred in 35 (17%); 12 women (26%) 
and 23 men (15%). In 31 of these patients, free T4 or total T4 
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were available, and on the basis of this, five were diagnosed with 
overt HT and 26 with SHT. 
The ultimate incidence of HT estimated from the mixture model 
was 26%, which corresponded to the 5-year risk. Figure 3 demon-
strates that HT is most likely to develop within the first two to 
three years after RT. 
Both logistic and mixture multivariable analysis found that higher 
Dmean and a small Vthyroid were significant risk factors for HT. Radia-
tion technique (concomitant boost technique in the initial treat-
ment period vs. integrated boost (IMRT) in the last period) was a 
significant factor in logistic analysis, but not when taking latency 
into account. None of the other factors were significant in multi-
variable analysis, including concomitant weekly Cisplatin. 
Two NTCP models were developed that included the two signifi-
cant factors from the multivariable analysis, Dmean and Vthyroid 
(Figure 4). NTCP values were calculated from the following equa-
tions: 
NTCP= (1+exp(-s))-1 
 
Logistic model: 
S=-2.019 + (0.0821 * Dmean) - (0.189 * Vthyroid) 
 
Mixture model: 
S= -1.235 + (0.1162 * Dmean) - (0.2873 * Vthyroid) 
 
On the basis of the mixture NTCP model, we proposed dose con-
straints for the thyroid gland in RT treatment planning of 26 Gy, 
38 Gy, 48 Gy and 61 Gy (Dmean) to keep the 5-year risk of RIHT 
below 25%, for thyroid volumes of 10, 15, 20 and 25 cm3, respec-
tively.  
Two methods for analyzing clinical data after RT of HNSCC pa-
tients were demonstrated, a logistic model and a mixture model 
that took latency into account, and these results showed the 
importance of taking latency into account in NTCP modeling.  
 
Conclusion: 
Biochemical hypothyroidism is a frequent late effect after radio-
therapy, with an estimated 5-year incidence of 26% in a HNSCC 
cohort. The risk of RIHT is significantly associated with small pre-
treatment thyroid volumes and high thyroid mean dose. Compari-
son of the logistic and mixture models demonstrated the im-
portance of latent-time correction in NTCP modeling. Individual 
dose constraints based on thyroid volume should be considered 
in radiation treatment planning. 
 
 
Figure 3. Cumulative events (with 95% CI) are shown on the left Y-
axis, indicating the time to development of HT if HT occurs. Cu-
mulative incidence (without 95% CI) of HT in the study population 
is shown on the right Y-axis. 
 
Figure 4. NTCP models at thyroid volumes of 10, 15, 20 and 25 
cm3, for the mixture model with 95% CI (blue lines) and the lo-
gistic model with 95% CI (red lines). 
 
Variation of normal tissue complication probability (NTCP) esti-
mates of radiation-induced hypothyroidism in relation to chang-
es in delineation of the thyroid gland (Paper II)  
This study assessed the impact of intra- and inter-observer varia-
bility in delineation of the thyroid gland on the risk estimates 
from the derived mixture NTCP model in Study I. Small mean 
(systematic) differences were found in intra- and inter-observer 
variability in Vthyroid, 0.4 cm3 (SD±1.6) and 0.3 cm3 (SD±1.8), and in 
Dmean, -0.5 Gy (SD±1.0) and 0.0 Gy (SD±1.3), respectively (Fig. 5). 
The corresponding mean differences of the estimated NTCP val-
ues for RIHT due to intra- and inter- observer variations were 
small at -0.4% (SD±6.0) and -0.7% (SD±4.8), respectively. Howev-
er, as demonstrated in Fig. 5 E and F and by the relatively large SD 
on the estimated risk of RIHT, there may be large differences in 
estimated risk for the individual patient due to variability be-
tween delineations.   
Mean Sørensen-Dice similarity index was 0.88 (SD± 0.03) for intra-
observer delineations and 0.85 (SD ±0.04) for inter-observer 
delineations.  
The spatial differences in delineated thyroid gland volume 
showed that the most pronounced mean (systematic) variability 
was around the middle of the thyroid gland. For the majority of 
the surfaces, a variability of ±0.02 cm was found in both intra- and 
inter-observer plots. The highest local random variations were in 
the caudal and medial parts of the lobes, with a local SD of ± 0.1-
0.2 cm. For the majority of the surfaces, random variation with 
local SD of ± 0.06-0.1 cm was found. This demonstrates that the 
local variation in delineations is generally small.  
 
Conclusion: 
The variation in predicted risk of RIHT was small for the study 
population as a whole. The derived NTCP model was shown to be 
robust towards observer variation in delineation of the thyroid 
gland. However, for the individual patient, there might be pro-
nounced differences in estimated risk due to this variation, as 
reflected by the relatively large SDs of the risk estimates. 
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Figure 5. Bland-Altman plots demonstrating intra-observer (left 
column: A, C , E) and inter-observer (right column B, D, F) varia-
tion in delineated volume (A, B), calculated mean dose (C, D) and 
variations in estimated risk of radiation-induced HT (E, F). 
 
Validation of a normal tissue complication (NTCP) model for 
radiation-induced hypothyroidism in two independent cohorts 
(Paper III) 
A cohort of 198 patients (cohort2) was obtained after a single 
assessment of TSH after RT. There were no statistical differences 
between cohort1 and cohort2 on most patient characteristics, 
however, Dmean and baseline TSH were significantly lower in co-
hort2.  
Analyses using the mixture model with a fixed time factor were 
performed on cohort1, cohort2 and the sampled cohort1S. High 
Dmean and a small Vthyroid were found to be significant risk factors 
in all three cohorts. Baseline TSH was significant in cohort2; how-
ever, this was not included in the NTCP model, due to the deci-
sion to develop a model equivalent to the NTCP model from 
cohort1 (NTCP1).  
Direct comparison of NTCP1 and the NTCP model (NTCP2) from 
cohort2, was not possible due to a discrepancy in the number of 
TSH samples. This was corrected for by developing a further NTCP 
model from cohort1 (NTCP1S) with just a single sample from each 
patient. When the number of TSH assessments was taken into 
account, the estimated risks were similar. Figure 6 shows dose-
response curves for the three NTCP models. Differences in esti-
mated risk between NTCP1 and NTCP2, and NTCP1S and NTCP2 
are shown in Figure 7. 
The NTCP model previously developed from cohort1 was: 
NTCP = (1+exp (-S))-1 , where: 
S=-1.235 + (0.1162 * Dmean) – (0.2873 * Vthyroid) 
 
The NTCP models for cohort1S and cohort2 with fixed latent time 
distribution resulted in the following values: 
NTCP1S:  S= -4.9177 + (0.18 * Dmean) – (0.30 * Vthyroid) 
NTCP2:    S= -4.7071 + (0.17 * Dmean) – (0.28 * Vthyroid) 
 
The clinical recommendations and the latency function from 
study I were not validated in this study due to the differences 
between the cohorts. 
 
Conclusion: 
As in study I, this validation cohort showed that, a small pre-
treatment thyroid volume and high mean dose were significant 
risk factors for RIHT. Direct comparison between the previously 
developed NTCP1 model and the NTCP2 model from the valida-
tion cohort was not possible. When taking the number of TSH 
assessments was taken into account, however, the two new 
models NTCP1S and NTCP2 were similar. 
 
 
Figure 6. Dose-response curves for the three NTCP models for 
selected thyroid volumes: NTCP1 (black), NTCP1S (red) and NTCP2 
(blue). 
 
 
Figure 7. A) The risk of developing RIHT, estimated from NTCP1 
(multiple blood samples) and NTCP 2 (single blood samples). B) 
The risk of RIHT, estimated from NTCP 1S and NTCP2 (both one 
blood sample). 
DISCUSSION 
The three studies in this thesis address risk predictions of radia-
tion-induced hypothyroidism (RIHT) after treatment for head and 
neck squamous cell carcinoma, as well as validation issues in 
relation to a normal tissue complication probability (NTCP) model 
for RIHT. 
 
Incidence of RIHT 
Study I estimated the 5-year actuarial probability and the ultimate 
probability of RIHT in cohort1 to be 26% [95% CI: 18-36%]. Most 
of the patients who eventually developed RIHT did so within the 
first two to three years after RT. A peak in development of RIHT 
1.5-3 years after RT is also reported in other studies 
[81,83,88,91,92,109]. Some have described late occurrences up to 
10-27 years after RT [81,84,85,94]. However, it should be noted 
that these studies do not consider other causes of HT. 
The actuarial probability in Study I is in accordance with findings 
from a number of previous studies [81,85,97], but was somewhat 
lower than in most studies of RIHT [88,91,94,99,101,102,107]. 
This lower incidence may reflect the exclusion of surgically treat-
ed patients and lower RT treatment doses, as described below.    
The high variability in reported incidence reflects the heterogene-
ity in study populations in the literature, which should be taken 
into account when comparing the studies. Surgery can significant-
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ly impact the risk of developing RIHT [89,115] and the incidence 
of RIHT is likely to be higher if surgical patients are included. 
The impact of a high radiation dose to the thyroid gland on the 
risk of RIHT is well established. This was demonstrated in Study I 
and III and is supported by many other studies [101,104,107-
109,115]. The actual doses absorbed by the thyroid gland should 
thus be considered when comparing incidences of RIHT and also 
during treatment planning to avoid RIHT.  
During the last 10-15 years, the addition of chemotherapy has 
become standard in curative treatment of HNSCC. However, in 
contrast to surgery, concomitant chemotherapy (i.e. platinum and 
5-FU) of HNSCC does not seem to increase the risk of RIHT 
[101,102,115], as supported by our findings. Nor did we find 
gender to be a risk factor, in contrast to other studies [84,96,97].  
Pretreatment Vthyroid on the other hand, was found to significantly 
affect the risk of RIHT in Study I and III. This finding has also re-
cently been noticed in other clinical studies [91,100,101,109]. 
One explanation for this is the new ability to consider and deter-
mine the thyroid volumes in CT-based dose planning systems. 
Alterio et al. [96] suggested that relatively higher levels of TSH 
were due to the smaller glands in women. This is supported by 
the findings in Study I, where, women had significantly smaller 
Vthyroid than men, but in subgroup analyses Vthyroid retained its 
significance in both men and women. 
 
Do we need an NTCP model for RIHT? 
As the cancer-specific survival for locally advanced HNSCC has 
doubled in Denmark since the first DAHANCA studies in the 1970s 
[116], the prevalence of HNSCC has increased as well. Due to the 
possible long-term consequences of hypothyroidism, dose con-
straints for the thyroid gland are needed in treatment planning 
for radiotherapy.  
The clinically acceptable risk of RIHT is a matter of debate. 
However, target coverage of tumor volumes should never be 
compromised to reduce the dose to the thyroid gland. We pro-
pose to keep the risk of RIHT below 25% with respect to individual 
thyroid volumes, i.e. keeping thyroid Dmean below 26 Gy, 38 Gy, 48 
Gy and 61 Gy for thyroid volumes of 10, 15, 20 and 25 cm3, re-
spectively. The recommendation of taking both Dmean and Vthyroid 
into account is supported by Boomsma et al [101]. Others have 
recommended the use of threshold values for constraints, using 
different percentage values of V30 [99,100,107], V45 [108,109] and 
V50 [110]. However, due to the high correlation between these 
dose-volume parameters, we found that Dmean was a relevant 
descriptor of the dose distribution within the thyroid gland (dis-
cussed in the section “Statistical considerations”). 
Knowledge about the dose-response relationship in an OAR ena-
bles us to balance the radiation dose to that organ against the 
dose to the surrounding normal tissues. Also of importance is that 
if the dose is below the tolerance level of an organ, the effect of 
further dose reductions may be negligible. Defining constraints 
for the thyroid gland allows for treatment planning optimization 
of thyroid doses in relation to other OARs in the neck area, includ-
ing the brain [117], the pituitary [118], the parotid [119] and 
submandibular glands [120], swallowing organs [28,121] and the 
larynx [122]. Median Dmean was significantly lower in cohort2 than 
cohort1, which may be ascribed to a dose-planning strategy that 
had been implemented at AUH to reduce treatment dose to the 
larynx (to reduce the risk of radiation-induced dysphagia), and led 
to a lower dose to the adjacent thyroid gland. This is in accord-
ance with two other studies that have found that doses to the 
thyroid gland were higher in IMRT plans than 3D-CRT, when the 
thyroid gland was not included as a constraint during the dose 
optimization process [91,106]. However, thyroid doses could be 
reduced and target coverage maintained using a thyroid dose 
constraint [91].  
 
Uncertainties of NTCP models 
Study II showed that, for the study population as a whole, the 
NTCP estimates of our mixture model were robust against ob-
server variability in delineation of the thyroid gland and the cor-
responding variability in Dmean. The low variability between thy-
roid gland delineations may due to the thyroid gland being 
relatively well-defined on CT scans because of its well vascular-
ized tissue [123] and high content of iodine [124,125]. For some 
individual patients, however, there were considerable differences 
in estimated risk of RIHT (up to 26%), especially when the esti-
mated risk of RIHT was on the steep part of the dose-response 
curve. Hence, precise delineation of the thyroid gland is still of 
importance for consistency of NTCP estimates.  
Figures 4 and 6, as well as Table 3 in Paper I, show the 95% CI of 
our estimated dose-response curves and suggested thyroid con-
straints. These demonstrate that it is important to consider not 
only the numerical value, but also the statistical uncertainty of an 
NTCP estimate or constraint in treatment planning. Furthermore, 
it must be kept in mind that a population-based NTCP model is 
only a prediction based on a standard population, thus there can 
be large uncertainties in the predicted probability for an individu-
al patient, who typically deviates from the average population. 
Marks et al. [126] used the term “host factors” to describe specif-
ic biological features that might affect radiation sensitivity in the 
individual. In the current context, these might be the presence of 
thyroid autoantibodies or thyroid nodularity before RT. The pres-
ence of autoantibodies and their impact on the risk of RIHT is not 
fully elucidated [50,89,105] and should be considered in future 
NTCP modeling studies, or at least when assessing the individual 
patient risk of developing RIHT.  
Despite all the uncertainties related to NTCP models, they will 
often be our best recommendation for considering effects on 
normal tissues and are therefore valuable tools for optimization 
of dose planning. 
 
Choice of endpoint 
Biochemical hypothyroidism was chosen as the endpoint for 
statistical analyses and NTCP modeling. This is the usual endpoint 
in RIHT studies, in both the clinical [50,82,84,86,87,91-96,109] 
and radiobiological [101,102] settings and corresponds to a grade 
1 or more toxicity on the CTCAE classification [127] and the ana-
lytical SOMA/LENT classification [128]. A single TSH assessment 
above the normal range was classified as an event, as also used in 
epidemiological studies. So far, only one group studying RIHT has 
used two elevated TSH assessments as endpoint [99,100]. The 
choice of endpoint reflects the choice of a pragmatic, patient-
centered approach to the development of NTCP models rather 
than a mechanistic and biology-centered approach [36]. A TSH 
level >4.0 (irrespective of the baseline TSH value) leads typically 
to clinical action such as further blood tests, additional control or 
follow-ups, or possibly Levothyroxine treatment. Other endpoints 
could also have been chosen, and a biological effect measure was 
in fact evaluated.  
As stated in Paper I, we also analyzed the data using the change in 
TSH (ΔTSH >2.7 mIU/l) from baseline to follow-up as endpoint. 
This threshold was chosen to produce the same number of pa-
tients developing RIHT as with the clinical endpoint of TSH>4.0. 
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From a biological point of view, the endpoint expressing a certain 
change in TSH might be the best predictor of biological changes in 
the thyroid gland after RT. The analyses with either TSH >4.0 or a 
ΔTSH >2.7 as endpoint resulted in very similar dose-response 
curves, as most patients who experienced an event were classi-
fied as experiencing an event using either endpoint. 
 
Uncertainties in TSH assessments 
TSH assessments can vary considerably. This was not taken into 
account either in our studies, or in any other studies of RIHT.  
Uncertainties in TSH assessment can be divided into pre-
analytical, analytical and biological variation [129-131]. Pre-
analytical variability relates to the blood sampling procedure as 
well as handling and storage of blood samples. The blood samples 
in our studies were taken in a routine setting. Analytical variability 
relates to the uncertainties of the assays used for TSH analysis.  
Biological variation can be divided into intra- and inter-individual 
variations. Intra-individual variation is due to the circadian varia-
tion in serum TSH, with the lowest levels occurring in daytime and 
a nocturnal rise of more than 100% that peaks after midnight 
[132]. A decrease of up to 50% may be observed from 8:00 to 
9:30 in the morning [133]. Moreover, the degree of glycosylation 
of TSH, non-thyroidal illness, weight change, pregnancy [134] and 
different medications [134,135] may affect individual TSH levels. 
There is substantial inter-individual variation in TSH assessments 
[136], demonstrated by the finding that individual 95% CI are 
approximately 50% of the reference range for TSH [137]. The 
relatively narrow individual reference range of TSH in the wide 
population-based reference range supports the use of ΔTSH as 
the endpoint for NTCP modeling of RIHT. However, as stated 
above, the 'patient-centered' endpoint (TSH>4.0) demonstrated 
similar dose-response relationships to those obtained from ΔTSH 
analysis.   
 
Validity of the NTCP model 
In the QUANTEC report, Bentzen et al. [41] introduced three 
concepts for validation of NTCP models: face validity, internal 
validity and external validity. Face and internal validity can be 
related to the mixture model (NTCP1) developed in Study I and 
external validity to Study III.  
 
Face validity  
Face validity relates to whether the findings of a study are rea-
sonable. As expected in study I, an increasing radiation dose to 
the thyroid gland increased the risk of hypothyroidism. The dose-
response relationship for development of RIHT is supported by 
most studies [80,82,84,95,98,99,108,109] and Dmean has generally 
been used as dose parameter in corresponding NTCP models for 
RIHT [101,102]. 
 The thyroid gland is considered to be a “parallel organ” [138] 
with the follicle cells as functional subunits that are independent 
of their neighbor cells. In this context, Dmean is considered an 
appropriate dose parameter for predicting normal tissue toler-
ance levels, equivalent to radiobiological investigations of other 
parallel organs like the parotid glands [119], lung [139], and liver 
[140]. Vthyroid was not expected to predict the risk of RIHT. How-
ever, as mentioned before, the importance of Vthyroid was subse-
quently supported by other studies of RIHT [91,100,101].  
The study findings appeared intuitively correct and the dose-
response curves “made sense” in that the risk of RIHT was zero 
(or close to) at dose zero and the confidence intervals were rea-
sonable in relation to our sample size and number of events. The 
NTCP1 model was therefore considered as having face validity. 
 
Internal validity  
Internal validity is a consideration of how well the model de-
scribes the data. This is typically assessed by plotting the ob-
served results against those predicted by the model. However, 
the mixture model predicts the risk of RIHT to infinite time, while 
our observation period varied in length from months up to nine 
years. The predicted risk by the mixture model was thus expected 
to be higher than the observed risk. Internal validity was there-
fore explored in an additional way, by plotting the dose-response 
curves from our models in conjunction with the actual patients 
being either responders (equal to 1) or non-responders (equal to 
0). This plot demonstrated that there were no events when Dmean 
was <25 Gy and the number of events in relation to non-events 
increased with increasing dose on the correspondingly rising 
dose-response curve.  
The data seemed reasonable for both the logistic curves and the 
curves of the mixture model. Furthermore, when the likelihood 
ratio test was used to test the statistical significance of adding 
other parameters to the model, no other factors than Dmean and 
Vthyroid were statistically significant for the final models. It is thus 
reasonable to conclude that the mixture model has internal valid-
ity in this study. 
 
External validity  
External validity relates to how well our mixture model describes 
other datasets. During the planning of Study III, the meaning of 
validating a model was considered whether the parameters of the 
model or the full NTCP model should be validated. The parame-
ters of two models might be different, but if they mutually bal-
ance each other in the full model so that the risk estimates of the 
two models are similar, the overall clinical impact of the two 
models are identical which is a way to seek model validation.  
Validation of the full model was chosen because it was consid-
ered that risk estimates and the corresponding tolerance levels 
were of interest and relevance in daily clinical radiotherapy prac-
tice. The aim was then to develop an NTCP model for use in 
treatment planning, hence, this approach to validation of the 
model. Data in Study III were thus analyzed in the same way as 
the mixture model in Study I.  
NTCP1 was not directly comparable with the NTCP model devel-
oped in the independent cohort (NTCP2), despite recruitment of 
another large study population. It became evident that the num-
ber of TSH assessments and the definition of endpoint had a 
significant impact on risk estimates. 
Due to the variability in TSH assessments, the probability of expe-
riencing an event increases with repeated assessments, when 
only one assessment of TSH>4.0 defines an event. 
Accounting for latency by the mixture model, i.e. considering 
events occurring at various time-points after treatment, would 
allow the two study cohorts to be compared despite their differ-
ing observation times. But the latency function could not be 
validated in cohort2 due to only one TSH assessment. A sampling 
of an identical number of measurements in cohort1 allowed a 
comparison between the NTCP1S and NTCP2 models, and they 
(and the corresponding model parameters) were very similar.  
The aim of validating the NTCP model was not fully achieved. 
However, Dmean and Vthyroid were also significant risk factors in 
cohort2, and the NTCP models became very similar when the 
number of TSH assessments was taken into account. It is conclud-
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ed that the NTCP model has external validity and at least, the 
model cannot be rejected. 
 
Methodological and statistical considerations 
Study I 
A retrospective design was chosen for this study, both to obtain a 
study cohort of at least 150 patients and to obtain follow-up over 
several years for at least a proportion of the included patients. 
This design gave two main limitations to take into account when 
choosing the statistical methods for data analysis: 
1. The variable number and timing of TSH assessments af-
ter radiotherapy. 
2. The considerable variation in follow-up time (median 25 
months, range 2-94 months), and thus the probability 
that some patients would develop hypothyroidism after 
the last TSH assessment (time censoring).  
 
Analysis was first done using a logistic regression model. Due to 
the above limitations, the standard logistic regression might 
underestimate the risk of HT so the data were analyzed using a 
mixture model taking latency into account [39,112]. The accumu-
lated Weibull distributions used for analyses represent flexible 
time distributions, and the time probability distribution is mod-
eled based on the observed data. Paper I shows a comparison of 
data analyses using standard logistic regression and the mixture 
model, shown in Figure 4 [103]. The mixture model is our pre-
ferred model, and was used for modeling in Study III. 
A review of the DVH’s for the thyroid showed that Dmean was a 
simple descriptor for dose-distribution in the studied glands. We 
did not find any other parameter (i.e. V20, V30, etc.) to be a better 
predictor of the risk of RIHT. For example, if high doses were 
more harmful that could be demonstrated by Dmean (unpublished 
data). Dmean was highly correlated with the other dose-volume 
parameters.  
NTCP modeling was done using physical doses and not fraction-
size corrected doses, due to the lack of quantitative estimates of 
the fraction sensitivity (α/β-ratio) of the thyroid gland. An at-
tempt was made to estimate the α/β-ratio for the thyroid gland 
from the dose distributions found in this study. However, this was 
not possible due to the small variations in dose distribution in the 
glands receiving almost the same Dmean. Consequently, the DVH’s 
could not be reduced to equivalent uniform doses used for esti-
mation of more advanced models like a Lyman-Kutcher-Burman 
model (e.g. to evaluate the adverse effects of a high dose to a 
small part of the gland, compared to a low dose to the whole 
gland). By using physical doses, the risk estimates are directly 
applicable in the clinical setting.  
The 95% CIs for the NTCP models were derived by bootstrap 
(Monte Carlo simulation). Bootstrap is a non-parametric method 
that allows estimation of the size of the model’s uncertainties. 
This is done by drawing new samples with replacement from the 
original data, under the assumption that the study sample is 
representative for the entire population [141,142].  
The strength of the study was inclusion of the largest cohort used 
for NTCP modeling of RIHT, comprising only patients treated with 
definitive RT and without surgery. Additionally, the cohort was 
representative for the patient population treated at our depart-
ment in that period, with three-quarters of the cohort being men. 
The exact radiation doses to the thyroid gland were calculated 
from the clinical treatment planning system. Delineation of the 
thyroid gland by one observer is thought to be a strength in mod-
eling studies, but this can be discussed in the light of our findings 
in Study II. 
The limitations of the study relate to its retrospective design, the 
considerable variation in number of TSH assessments and the 
length of follow-up. Using the hospital database is a possible 
source of selection bias, There may have been over-selection of 
patients with symptoms of hypothyroidism (who had TSH as-
sessed) resulting in a potential overestimation of RIHT, especially 
before 2008 when routine assessment of TSH after radiotherapy 
was established. However, the criteria of a normal baseline TSH 
and inclusion of patients from the DAHANCA 10 study should 
partly compensate for this effect.  
 
Study II 
This study was designed to investigate intra- and inter-observer 
variability in delineation of the thyroid gland, and subsequent 
variability in calculated dose to the thyroid gland and estimated 
risk of RIHT by the mixture NTCP model. The advantages and 
disadvantages of three main approaches (comparison of delineat-
ed volumes, overlap measures and Hausdorff distance) are dis-
cussed below.  
Comparison of delineated volumes is the most common approach 
for assessing variability in organ delineation [143]. A limitation of 
this method is that it gives no information about overlap: two 
structures might have the same volume, but different locations. 
In this study, the variability of delineated Vthyroid, Dmean and esti-
mated risk of RIHT were assessed using Bland-Altman plots. These 
plots allow visual assessment of measurement error (both sys-
tematic and random) of continuous variables [113,144].  
Overlap measures take both volume and location into account. 
Two commonly used approaches are the Sørensen-Dice Similarity 
index (DSI) and the Jacard similarity index (JSI) (also called con-
cordance index) [145]. The definitions of the two indexes are 
different but related; both have the value of 1 when there is 
perfect overlap between two structures, and a value of 0 when 
there is no overlap. However, the index for the same partial over-
lap is different, and the interpretation of values between 0 and 1 
is not straightforward. DSI has been shown to be a special type of 
kappa statistics [146], and thus, a DSI >0.7 is commonly referred 
to as good agreement. We calculated DSI to facilitate comparison 
with other studies. DSI is a relative measure, however, and large 
structures are more likely to have higher DSI than small structures 
with the same variability [147,148]. Comparisons of DSI values 
should thus be limited to delineation studies of one specific or-
gan. Another limitation of overlap measures is that they do not 
provide information on how contours may vary quantitatively in 
size, shape or location in absolute terms [143]. 
Hausdorff distance is often used to assess variation between 
delineations. For two surfaces, Hausdorff distance is defined as 
the maximum distance from any point on one surface to the 
closest point on the other surface [149]. It does not describe local 
variations, however, and there is no standard method for as-
sessing local variability between delineations. Different 3D mod-
els of surface variation can thus be used. Brouwer et al. [150] 
assessed the local variation in five distances to the median (SD) of 
the delineations to obtain a model of global 3D SD. We developed 
a method for displaying both systematic deviations (mean values) 
and random variations (SD) in local variation, using the center of 
mass as origin and measuring the distance between the contours.  
Strengths of the study were inclusion of a considerable sample 
size, judged to be representative for the population included in 
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Study I, and the use of different methods to study the variability 
in thyroid gland delineation. 
A limitation was the low number of observers. This was ad-
dressed in Paper II by analyzing the impact of extreme systematic 
variations on the estimated NTCP. Despite this, we cannot rule 
out an impact of local delineation traditions or training as the 
reason for the small systematic variation between delineations.  
 
Study III 
The aim of this study was to validate the mixture NTCP model 
developed in Study I (cohort1, OUH) in an equivalent cohort 
treated at a different hospital (cohort2, AUH). Patients at both 
hospitals were treated according to DAHANCA guidelines and the 
same inclusion and exclusion criteria were applied in both stud-
ies.  
It became evident during analysis that there were some differ-
ences between the two cohorts that had not been considered as 
a limitation during planning of the study. While the difference in 
number of TSH assessments for two cohorts was adjusted for by 
the sampling of cohort1S, latency could not be estimated due to 
very large uncertainties on the estimates. Bentzen et al. [112] 
have previously estimated latency in late skin reactions from a 
single follow-up, hence the assumption that this would be possi-
ble in cohort2. Both the sampling of a new cohort and the use of 
a fixed time factor from Study I might have been avoided by 
planning additional follow-ups and a study period to obtain more 
TSH assessments.  
Baseline TSH was a significant risk factor in cohort2, but was not 
included in the model because we wanted to study an NTCP 
model equivalent to our model from cohort1, which only included 
Vthyroid and Dmean.  
A strength of the study was the inclusion of a similar size cohort 
as in Study I. As we used the same inclusion and exclusion criteria 
as in Study I, and included consecutive patients from the outpa-
tient clinic, we believe that the cohort is representative for pa-
tients treated with definitive radiotherapy at AUH. The blood 
samples were analyzed in the same laboratory in Studies I and III.  
Limitations of the study were the partly retrospective design and 
the limited number of follow-up TSH assessments (as discussed 
above). A bias in baseline TSH due to the timing of blood sampling 
is conceivable, since most of the patients had their baseline TSH 
during the first two weeks of radiotherapy. At this time the radio-
therapy may theoretically have caused thyroiditis, which could 
have affected (typically lowering) the TSH levels.  
 
CONCLUSION AND PERSPECTIVES 
Radiation-induced hypothyroidism (RIHT) is a frequent late effect 
after definitive radiotherapy for head and neck squamous cell 
carcinoma. Dose constrains for the thyroid gland should thus be 
applied in radiation treatment planning to avoid RIHT, without 
compromising target coverage. Dmean and Vthyroid were significant 
risk factors for RIHT in two independent patient cohorts. Both 
factors were included in the NTCP models developed in Study I 
and III, that provide suggested dose constraints in relation to 
specific thyroid volumes.  
Validation of the input data for the NTCP1 model (Study II) 
showed it to be robust against observer variations in delineations 
of the thyroid gland at the population level. There may be pro-
nounced differences in estimated individual risk of RIHT, howev-
er. Precise delineation is thus of utmost importance. 
The NTCP1 model could not be fully validated and could not be 
directly compared to NTCP2. However, when the number of TSH 
assessments was taken into account, the estimated risks were 
very similar.  
In light of the frequent occurrence of RIHT, and the potential 
repercussions of leaving this untreated, we recommend routine 
follow-up of thyroid function with regular TSH assessments after 
radiotherapy to the head and neck region. Since RIHT predomi-
nantly developed within 2-3 years after radiotherapy, routine TSH 
assessments in the first five years may suffice, and not lifelong as 
proposed by others [81,88,94].  
The current studies have provided an NTCP model for RIHT and 
dose constraints for the thyroid gland that can be implemented in 
a clinical setting. Further validation of the model and dose con-
straints is desirable, however, in view of the uncertainties of 
NTCP models. Different strategies can be used for this. Despite 
the very similar risk estimates by NTCP1S and NTCP2, validation 
by obtaining more TSH assessments and a longer follow-up in 
cohort2 should be considered for validating the latency function 
and to form the basis for guidelines for follow-up assessment of 
thyroid function after radiotherapy. Pooling of data from more 
studies has been proposed for validation of NTCP models [151] as 
was done for establishing dose constraints for the parotid glands 
[119]. Pooling of the data from cohort1 and cohort2, and poten-
tially data from other centers/countries with a longer follow-up, is 
an option that could be used to establish dose-response models 
on a very large cohort. To that end, uniform reporting of the data 
is needed. In support of this, we recommend biochemical hypo-
thyroidism as an endpoint for modeling, with the possibility for 
further division of patients into subclinical and overt hypothyroid-
ism. 
The ultimate goal for further validation of the model is a pro-
spective, longitudinal study with standardization of TSH assess-
ments. Such a study could also include patient-reported out-
comes, such as quality of life, in relation to RIHT. Furthermore, 
regular assessment of thyroid function might uncover the at-
tributable factors and course of subclinical hypothyroidism after 
radiotherapy. Is it an inevitable road to overt hypothyroidism, or 
does remission occur? 
ABBREVIATIONS 
 
 
 DANISH MEDICAL JOURNAL   14 
SUMMARY 
Head and neck cancer is the sixth most common cancer in the 
world. In Denmark the incidence was 1,287 in 2013 (thyroid can-
cer excluded). Head and neck cancer is predominantly a loco-
regional disease, and radiotherapy (RT) and surgery are major 
treatment options. Approximately 70% of Danish patients receive 
definitive RT, and the rest are treated with surgery with or with-
out postoperative RT.  
Radiation to the normal tissues is inevitable during RT. The cur-
rent advanced treatment modalities allow precise calculation of 
radiation doses to normal tissues and there is a potential to dis-
tribute the dose to avoid adverse effects from radiation. Howev-
er, this requires knowledge about the radiation tolerance levels of 
individual organs. Radiation-induced hypothyroidism (RIHT) is a 
well-known late effect of radiation to the thyroid gland, which can 
develop months to years after RT. The reported incidence of RIHT 
varies considerably, however, and the tolerance level of the thy-
roid gland is poorly defined. The aim of this PhD project was thus 
to elucidate these issues. 
The first study included a cohort of 203 patients with head and 
neck cancer who were treated with definitive RT and no surgery 
at Odense University Hospital, Denmark, in 2002-2010. Analysis of 
patient characteristics, precise radiation doses to the thyroid 
gland and follow-up assessments of thyroid function after radio-
therapy gave an estimated 5-year incidence of RIHT of 26%. Sig-
nificant risk factors for the development of RIHT were a small 
thyroid volume and a high mean radiation dose to the gland. Two 
models were developed for predicting the risk of RIHT, taking 
both the thyroid volume and the mean radiation dose into ac-
count. One model was based on the collected data alone, while 
the other model included an estimated time distribution for the 
development of RIHT (i.e. latency). Using the model that consid-
ered latency, dose constraints for the thyroid gland were pro-
posed for keeping the risk of RIHT after radiotherapy below 25%. 
This model emerged as the preferred model, and its robustness 
was tested in the following two studies. 
The second study aimed at assessing the impact of variation of 
estimated risk of RIHT due to intra- and inter-observer variability 
in delineated thyroid gland volume. Fifty treatment plans were 
randomly chosen for either repeat delineation by the author 
(intra-observer) or delineation by another radiation oncologist 
(inter-observer). The variations in delineated thyroid gland vol-
ume and mean radiation dose, and the subsequent variation in 
estimated risk of RIHT were assessed. For the entire study popula-
tion, the variation in predicted risk of RIHT was small and the 
model was robust towards observer variations in delineation of 
the thyroid gland. However, for some patients there were pro-
nounced differences in the estimated risk due to variation in 
organ delineation, and thus precise delineation is of utmost im-
portance for the individual patient.  
The third study aimed at studying the robustness of the model in 
a cohort of head and neck cancer patients treated with definitive 
RT at the Department of Oncology, Aarhus University Hospital. 
198 patients were included after one assessment of thyroid func-
tion (blood sample of thyrotropin, TSH) during routine follow-up 
after radiotherapy. A small thyroid volume and a high mean radia-
tion dose were also found to be significant risk factors for radia-
tion-induced hypothyroidism in this cohort. These factors were 
included in a new risk model. Direct comparison of the two mod-
els was not possible, however, due to a different number of TSH 
assessments in the two cohorts. It was also not possible to esti-
mate latency on the basis of a single measurement of thyroid 
function. Nevertheless, when the number of TSH assessments 
was taken into account, the estimated risk of RIHT was very simi-
lar in the two cohorts. 
 
Conclusion 
Hypothyroidism is a frequent late effect after definitive radio-
therapy. As the condition has been linked to increased risk of 
cardiac disease and mortality, and decreased quality of life, it is 
important to consider the risk of radiation-induced hypothyroid-
ism (RIHT) when planning radiation treatment. The size of the 
thyroid gland and the radiation dose to the gland are key factors 
in the development of RIHT, and both these factors should be 
considered when determining dose constraints for the thyroid 
gland. A risk of RIHT below 25% is recommended. Furthermore, 
routine assessment of thyroid gland function should be offered 
after radiotherapy in the neck area. Finally, the robustness of the 
risk model should be studied in a longitudinal follow-up of a co-
hort of patients with repeated thyroid function assessment. 
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